Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790287 | 0.85 | ACHE (0.53) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8790830 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8790935 | 0.83 | KMT2A (0.55) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8789055 | 0.82 | ACHE (0.58) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8789713 | 0.81 | KMT2A (0.51) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8790649 | 0.81 | ALDH1A1 (0.52) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8789220 | 0.80 | CDC25C (0.51) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8791400 | 0.78 | KCNH2 (0.52) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL3143902 | 0.77 | ACHE (0.65) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL8789063 | 0.77 | KCNH2 (0.60) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |